Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + ifosfamide + carboplatin + etoposide
- Development stage
- Unknown
- Lead developer
- Herbert Irving Comprehensive Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination chemotherapy regimen, consisting of high-dose paclitaxel followed by the ICE protocol (ifosfamide, carboplatin, and etoposide), was investigated by the Herbert Irving Comprehensive Cancer Center. It is primarily indicated for the treatment of lung cancer in the context of tandem autologous peripheral blood stem cell transplantation (PBSCT). The regimen works through multiple mechanisms: paclitaxel stabilizes microtubules to inhibit cell division, ifosfamide and carboplatin induce DNA damage through alkylation and cross-linking, and etoposide inhibits topoisomerase II to prevent DNA ligation. This intensive approach aims to achieve maximal cytoreduction in patients with advanced or high-risk lung cancer prior to stem cell rescue.
- Other names
- High-dose paclitaxel followed by ICEPaclitaxel-ICE regimenpaclitaxel-Herbert Irving Comprehensive Cancer Center-lung cancer
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on paclitaxel + ifosfamide + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + ifosfamide + carboplatin + etoposide.